Skip to main content

RETRACTION article

Front. Physiol.
Sec. Vascular Physiology
Volume 15 - 2024 | doi: 10.3389/fphys.2024.1505634

Retraction: OGT-mediated KEAP1 glycosylation accelerates NRF2 degradation leading to high phosphate-induced vascular calcification in chronic kidney disease

Provisionally accepted
Frontiers Editorial Office Frontiers Editorial Office *
  • Frontiers Media SA, Lausanne, Switzerland

This article is a retraction of:

  1. OGT-Mediated KEAP1 Glycosylation Accelerates NRF2 Degradation Leading to High Phosphate-Induced Vascular Calcification in Chronic Kidney Disease

    1. Read original article

The final, formatted version of the article will be published soon.

    Retraction: OGT-mediated KEAP1 glycosylation accelerates NRF2 degradation leading to high phosphate-induced vascular calcification in chronic kidney disease Please, find the retraction statement below: Tian-Hua Xu , Yinke Du , Zitong Sheng , Yue Li , Xiaobo Qiu , Binyao Tian and Li Yao (2020). OGT-mediated KEAP1 glycosylation accelerates NRF2 degradation leading to high phosphate-induced vascular calcification in chronic kidney disease. Frontiers in Physiology 11:01092. doi: 10.3389/fphys.2020.01092. “Following publication, concerns were raised regarding the integrity of the images in the published figures OR regarding the validity of the data presented in the article. The authors failed to provide the raw data or a satisfactory explanation during the investigation, which was conducted in accordance with Frontiers’ policies. Given the concerns about the validity of the data, and the lack of raw data, the editors no longer have confidence in the findings presented in the article. This retraction was approved by the Chief Executive Editor of Frontiers. The authors received a communication regarding the retraction and had a chance to respond. This communication has been recorded by the publisher.”.

    Keywords: GlcNAc transferase, Keap 1, Nrf2, Autophagy, High phosphorus, vascular smooth muscle cell, Vascular Calcification, Chronic kidney disease 3

    Received: 03 Oct 2024; Accepted: 03 Oct 2024.

    Copyright: © 2024 Editorial Office. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence: Frontiers Editorial Office, Frontiers Media SA, Lausanne, Switzerland

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.